Claybrook Capital’s Merck MRK Stock Holding History

Claybrook Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-31	Closed	-$5K	–	794
2018 Q3	$5K	Sell	31 -152	-83%	-$9.68K	﹤0.01%	169
2018 Q2	$14K	Buy	+183	New	+$10.3K	0.01%	147

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Claybrook Capital's MRK Position: Q2 2022 in Review

Claybrook Capital sold out of Merck (MRK) in Q2 2022, closing a stake of 28,909 shares — an estimated $2.37M sold.

Claybrook Capital first reported a position in MRK in Q4 2017 and held it in 18 quarters. The position peaked at $3.99M in Q2 2021. 3,013 funds tracked by Wall St. Rank hold MRK as of Q2 2022.

Claybrook Capital reported no remaining Merck position as of Q2 2022 after selling out during the quarter.
Claybrook Capital sold 28,909 Merck shares in Q2 2022, an estimated $2.37M.
Claybrook Capital first reported a position in Merck in Q4 2017 and held it in 18 quarters.
Claybrook Capital's Merck position peaked at $3.99M in Q2 2021.
3,013 funds tracked by Wall St. Rank held Merck as of Q2 2022.

Based on Claybrook Capital's 13F filing for Q2 2022, filed 18 Jul 2022.